

# Biomarker based adaptive development in Alzheimer disease (BioAdaptAD)

<https://www.neurodegenerationresearch.eu/survey/biomarker-based-adaptive-development-in-alzheimer-disease-bioadaptad-3/>

## Principal Investigators

JANSSEN PHARMACEUTICA

## Institution

JANSSEN PHARMACEUTICA

## Contact information of lead PI Country

Belgium

## Title of project or programme

Biomarker based adaptive development in Alzheimer disease (BioAdaptAD)

## Source of funding information

Flanders Innovation & Entrepreneurship

## Total sum awarded (Euro)

€ 2,241,280

## Start date of award

01/06/2013

## Total duration of award in years

4.0

## The project/programme is most relevant to:

Alzheimer's disease & other dementias

## Keywords

### Research Abstract

The general objectives of this project are to develop a BACE inhibitor for disease modification in Alzheimer's disease and to explore the development in an earlier prodromal Alzheimer's disease population. From a drug development perspective, this will involve multiple adaptation steps and the intensive use of biomarkers.

## Lay Summary

**Further information available at:**

**Types:**

Investments > €500k

**Member States:**

Belgium

**Diseases:**

Alzheimer's disease & other dementias

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A